{
  "id": "602c19e71cb411341a00011a",
  "type": "factoid",
  "question": "What is the mode of administration of AZD8601?",
  "ideal_answer": "AZD8601 is administered intradermally.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32438492"
  ],
  "snippets": [
    {
      "text": "Intradermal delivery of AZD8601, an mRNA designed to produce vascular endothelial growth factor A (VEGF-A), has previously been shown to accelerate cutaneous wound healing in a murine diabetic model",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32438492",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intradermal delivery of AZD8601, an mRNA designed to produce vascular endothelial growth factor A (VEGF-A), has previously been shown to accelerate cutaneous wound healing in a murine diabetic model.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32438492",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Intradermal"
}